The funding will primarily be allocated toward the submission of an application to British regulators to allow for the ...

Qnovia has received clearance from the US Food and Drug Administration (FDA) to start a clinical trial for its RespiRX ...

Qnovia announced that it raised $16 million in Series B funding to support its inhaled smoking cessation therapy platform.

In conclusion, NRT (nicotine gum or inhaler) doubled the quit rate compared ... 46.6 ± 10.0 (20–67) Age started smoking (years) 18.3 ± 3.3 (8–30) 18.6 ± 3.9 (12–42) Cigarettes smoked ...

Qnovia, a Richmond startup focused on smoking-cessation technology, has raised $16 million in a Series B round.

Inhaler: peak plasma concentrations of 49ng ... Nasal Spray antagonized by nasal vasoconstrictors (eg, xylometazoline). Smoking cessation potentiates theophylline, insulin, β-blockers ...

Qnovia, Inc., a pharmaceutical company who recently announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the RespiRx™ Nicotine ...

Smoking causes lung disease ... Relievers are often administered using a device called an inhaler. This lets you breathe the medicine in through your mouth and directly into your lungs.

Aerosol delivery devices are hand-held, portable drug delivery devices. They consist of suspension of solid or liquid particles in a carrier gas, which makes feasible for treatment of respiratory and ...